PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drug
PharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer).
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 342 entries.
Entries by Thomas Gabrielczyk
Diabetes combo improves regeneration of beta cells
14th February 2020 in News /by Thomas GabrielczykUsing a combination of approved diabetes drugs, a Swiss-US research team was able to support the regeneration of insulin-secreting cells in the pancreas.
JAKPot for treating bone loss
13th February 2020 in News /by Thomas GabrielczykResearchers report that JAK inhibitors a class of approved anti-inflammatory drugs prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis.
Mereo BioPharma raise money to back Phase III trials
12th February 2020 in News /by Thomas GabrielczykMereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund.
BIH scientists optimise CRISPR gene scissors
9th February 2020 in News /by Thomas GabrielczykTargeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".
Azafaros BV raises 25m in Series A round
6th February 2020 in News /by Thomas GabrielczykDutch biotech Azafaros B.V. has closed a 25m Series A financing round.
Researchers identify roots of childhood asthma
6th February 2020 in News /by Thomas GabrielczykInfants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.
MaaT Pharma raise 18m to advance clinical pipeline
5th February 2020 in News /by Thomas GabrielczykMaaT Pharma SA has announced 18m Series B financing to boost its microbiome biotherapeutics pipeline.
Stilla raises 20m in series B financing round
5th February 2020 in News /by Thomas GabrielczykFrench Stilla Technologies SA raised 20m in a Series B funding to boost digital PCR-based genetic testing.
Valneva raises US$85m
4th February 2020 in News /by Thomas GabrielczykFrench vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.